keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CPF-7 (Caerulein precursor fragment), an insulinotropic peptide, promotes insulin secretion and drives epithelial-mesenchymal transition via Snai1 upregulation in PANC-1 ductal cells. Moreover, it induces exocrine plasticity through Ngn3 upregulation, with applications in type 2 diabetes research [1] [2].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | CPF-7 (Caerulein precursor fragment), an insulinotropic peptide, promotes insulin secretion and drives epithelial-mesenchymal transition via Snai1 upregulation in PANC-1 ductal cells. Moreover, it induces exocrine plasticity through Ngn3 upregulation, with applications in type 2 diabetes research [1] [2]. |
In vitro | CPF-7 (50 nM; 7 days) induces the transdifferentiation of PANC-1 exocrine cells into pancreatic endocrine progenitor cells [1]. |
Synonyms | Caerulein precursor fragment |
Molecular Weight | 2586 |
Formula | C118H193N33O32 |
CAS No. | 103238-06-8 |
keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CPF-7 103238-06-8 Caerulein precursor fragment inhibitor inhibit